192 related articles for article (PubMed ID: 34571996)
1. Strategic Development of an Immunotoxin for the Treatment of Glioblastoma and Other Tumours Expressing the Calcitonin Receptor.
Gupta P; Hare DL; Wookey PJ
Cells; 2021 Sep; 10(9):. PubMed ID: 34571996
[TBL] [Abstract][Full Text] [Related]
2. Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma.
Gilabert-Oriol R; Furness SGB; Stringer BW; Weng A; Fuchs H; Day BW; Kourakis A; Boyd AW; Hare DL; Thakur M; Johns TG; Wookey PJ
Cancer Immunol Immunother; 2017 Sep; 66(9):1217-1228. PubMed ID: 28501939
[TBL] [Abstract][Full Text] [Related]
3. Building the case for the calcitonin receptor as a viable target for the treatment of glioblastoma.
Gupta P; Furness SGB; Bittencourt L; Hare DL; Wookey PJ
Ther Adv Med Oncol; 2020; 12():1758835920978110. PubMed ID: 33425026
[TBL] [Abstract][Full Text] [Related]
4. Expression and activity of the calcitonin receptor family in a sample of primary human high-grade gliomas.
Ostrovskaya A; Hick C; Hutchinson DS; Stringer BW; Wookey PJ; Wootten D; Sexton PM; Furness SGB
BMC Cancer; 2019 Feb; 19(1):157. PubMed ID: 30777055
[TBL] [Abstract][Full Text] [Related]
5. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
6. Nucleolin is expressed in patient-derived samples and glioblastoma cells, enabling improved intracellular drug delivery and cytotoxicity.
Balça-Silva J; do Carmo A; Tão H; Rebelo O; Barbosa M; Moura-Neto V; Sarmento-Ribeiro AB; Lopes MC; Moreira JN
Exp Cell Res; 2018 Sep; 370(1):68-77. PubMed ID: 29902537
[TBL] [Abstract][Full Text] [Related]
7. The expression of calcitonin receptor detected in malignant cells of the brain tumour glioblastoma multiforme and functional properties in the cell line A172.
Wookey PJ; McLean CA; Hwang P; Furness SG; Nguyen S; Kourakis A; Hare DL; Rosenfeld JV
Histopathology; 2012 May; 60(6):895-910. PubMed ID: 22335784
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
9. Targeting Glioma Stem Cells by Functional Inhibition of Dynamin 2: A Novel Treatment Strategy for Glioblastoma.
Luwor R; Morokoff AP; Amiridis S; D'Abaco G; Paradiso L; Stylli SS; Nguyen HPT; Tarleton M; Young KA; O'Brien TJ; Robinson PJ; Chircop M; McCluskey A; Jones NC
Cancer Invest; 2019; 37(3):144-155. PubMed ID: 30907150
[TBL] [Abstract][Full Text] [Related]
10. FK506 Attenuates the MRP1-Mediated Chemoresistant Phenotype in Glioblastoma Stem-Like Cells.
Torres Á; Arriagada V; Erices JI; Toro MLÁ; Rocha JD; Niechi I; Carrasco C; Oyarzún C; Quezada C
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208561
[TBL] [Abstract][Full Text] [Related]
11. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
[TBL] [Abstract][Full Text] [Related]
12. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.
Datta S; Sears T; Cortopassi G; Woolard K; Angelastro JM
Biomed Pharmacother; 2021 Jan; 133():111058. PubMed ID: 33378970
[TBL] [Abstract][Full Text] [Related]
13. Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma.
Jiang W; Finniss S; Cazacu S; Xiang C; Brodie Z; Mikkelsen T; Poisson L; Shackelford DB; Brodie C
Oncotarget; 2016 Aug; 7(35):56456-56470. PubMed ID: 27486821
[TBL] [Abstract][Full Text] [Related]
14. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells.
Spina R; Voss DM; Asnaghi L; Sloan A; Bar EE
Oncotarget; 2016 Jan; 7(1):459-72. PubMed ID: 26575950
[TBL] [Abstract][Full Text] [Related]
15. Targeting EZH2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway.
Zhao G; Deng Z; Li X; Wang H; Chen G; Feng M; Zhou Y
Exp Brain Res; 2023 Oct; 241(10):2409-2418. PubMed ID: 37644332
[TBL] [Abstract][Full Text] [Related]
16. The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy.
Mattei V; Santilli F; Martellucci S; Delle Monache S; Fabrizi J; Colapietro A; Angelucci A; Festuccia C
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917954
[TBL] [Abstract][Full Text] [Related]
17. Cancer Stem Cells: Significance in Origin, Pathogenesis and Treatment of Glioblastoma.
Biserova K; Jakovlevs A; Uljanovs R; Strumfa I
Cells; 2021 Mar; 10(3):. PubMed ID: 33799798
[TBL] [Abstract][Full Text] [Related]
18. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence.
Auffinger B; Spencer D; Pytel P; Ahmed AU; Lesniak MS
Expert Rev Neurother; 2015; 15(7):741-52. PubMed ID: 26027432
[TBL] [Abstract][Full Text] [Related]
19. Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.
Daniele S; Zappelli E; Natali L; Martini C; Trincavelli ML
Cell Death Dis; 2014 Nov; 5(11):e1539. PubMed ID: 25429616
[TBL] [Abstract][Full Text] [Related]
20. The Combined Treatment with Chemotherapeutic Agents and the Dualsteric Muscarinic Agonist Iper-8-Naphthalimide Affects Drug Resistance in Glioblastoma Stem Cells.
Guerriero C; Matera C; Del Bufalo D; De Amici M; Conti L; Dallanoce C; Tata AM
Cells; 2021 Jul; 10(8):. PubMed ID: 34440646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
